Key result
High-dose carmustine infusion was associated with clinical and electrocardiographic evidence of myocardial ischemia during and immediately after infusion in three patients without prior angina.
Why the study?
Does high-dose carmustine infusion cause myocardial ischemia in patients receiving treatment for solid tumors and lymphomas?
Case Report (n=3)
Does high-dose carmustine infusion cause myocardial ischemia in patients receiving treatment for solid tumors and lymphomas?
High-dose carmustine infusion may cause myocardial ischemia and should be monitored for cardiac toxicity.
Answers are grounded in this paper and cite their sources.
High-dose carmustine may trigger ischemia warranting monitoring; hypothesis-generating observation leaves causal confirmation open.
Carmustine (BCNU), a nitrosourea derivative, is an antineoplastic agent used recently for the treatment of human solid tumors and lymphomas in high doses with autologous bone marrow transplantation. Cardiac toxicity related to BCNU has not been described well. Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion. The incidence, cause, and mechanism of such a side effect are unknown but should be considered in patients receiving high-dose carmustine infusions.
No takes yet. Share an insight, caveat, or question.
Kanj et al. (1991) conducted a case report in Solid tumors and lymphomas (n=3). High-dose carmustine (BCNU) infusion was evaluated on Clinical and electrocardiographic evidence of myocardial ischemia. High-dose carmustine infusion was associated with clinical and electrocardiographic evidence of myocardial ischemia during and immediately after infusion in three patients without prior angina.
Synapse has enriched 10 related papers. Consider them for comparative context: